7 recruiting. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 7 |
| Phase 1 | 2 | Recruiting 2 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy Serplulimab, Second-Line Chemo/Targeted Therapy - Colorectal Cancer, Relapse | Phase 2 | Recruiting | Fudan University | 40 | 2026-05-10 | 2026-05-22 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate - Glioblastoma Multiforme, Relapse | Phase 2 | Recruiting | Université de Sherbrooke | 120 | 2025-08-01 | 2025-08-07 |
| Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia BITE and DLI - Leukemia, Relapse | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 31 | 2025-08-01 | 2025-08-06 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| IA Carboplatin + Radiotherapy in Relapsing GBM IA Carbo+ Radiation - Glioblastoma Multiforme, Relapse | Phase 1 / Phase 2 | Recruiting | Université de Sherbrooke | 35 | 2018-07-10 | 2025-08-11 |
Recurrence (7) · Glioblastoma (2) · Leukemia (2) · Colorectal Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Disease Attributes (7) · Neoplasms (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Neoplasms by Histologic Type (6) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Astrocytoma (2) · Glioma (2) · Hematologic Diseases (2) · Lymphoma (2) · Neoplasms, Germ Cell and Embryonal (2)
Azacitidine (1) · Decitabine (1) · Dental Occlusion (1) · Drug Therapy (1) · Insulin Infusion Systems (1) · loncastuximab tesirine (1) · venetoclax (1)
Université de Sherbrooke (2) · First Affiliated Hospital of Zhejiang University (1) · Fudan University (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Miami (1)
China (3) · Canada (2) · United States (2)
David Fortin, MD (2) · Juan Alderuccio, MD (1) · Natalie Grover, MD (1)
PMID 19534336, PMID 19760366, PMID 22284691, PMID 22931705, PMID 23844725, PMID 24026531, PMID 24947313